Navigation Links
Today on Capitol Hill: The Malaria Forum

- Interdisciplinary team of experts joins forces to discuss the latest tools to combat this preventable but deadly disease -

BRIDGEWATER, N.J., April 21 /PRNewswire/ -- Today on Capitol Hill Congressmen Don Payne and John Boozman, co-chairs of the Congressional Malaria Caucus, join global pharmaceutical company sanofi-aventis and the non-profit Drugs for Neglected Disease initiative (DNDi) to host the Malaria Forum. The Malaria Forum offers an important opportunity to gain insights on health initiatives and partnerships that are focused on combating this dreaded disease worldwide.

Every year, as many as one million people die from malaria and another 300-500 million suffer from it. Malaria remains the leading cause of death for children under the age of five in Africa, and kills one child every 30 seconds worldwide.

The sanofi-aventis group has been present in Africa for decades and extensively in countries affected by malaria. In 2001, the Impact Malaria initiative, the first program from the sanofi-aventis Access to Medicines team was created mobilizing the company's expertise and resources to fight diseases including malaria.

DNDi, an independent, non-profit pharmaceutical research and development (R&D) organization, has been involved in developing and making available needs-adapted treatments for a group of deadly neglected diseases traditionally ignored by market-driven mechanisms for drug development. Since its founding in 2003, DNDi has already developed and made available two antimalarial medicines while reaching out in partnership to those in the remotest areas in Africa as well as the largest pharmaceutical companies in the world.

Dr. Francois Bompart, who is part of the sanofi-aventis group's Access to Medicine team, will discuss the importance of educating communities, healthcare professionals and families about malaria and adapting medicines to meet patient needs. "Our mission is to bring together all of sanofi-aventis' expertise in order to provide patients in developing countries with access to medicines and vaccines for specific diseases, such as malaria. However, based on the knowledge that medicines alone cannot solve all problems we are also involved in education, information and prevention initiatives in these countries. We are deeply committed to our continued efforts in promoting better health for patients worldwide and to satisfy unmet healthcare needs."

Hellen Gelband, a malaria expert and member of the Board of Directors of DNDi North America, will discuss the impact and needs of patients with neglected diseases like malaria, with a focus on how the medicine, ASAQ (artesunate-amodiaquine)(1) was developed in partnership with sanofi-aventis. In addition, Ms. Gelband will discuss why various types of partners, from the public and private sectors, are critical in addressing the global health imbalance and how DNDi is utilizing a wide array of partnerships in its patient-driven drug development model, which is already delivering concrete benefits to patients in the form of two new malaria drugs in use in the field.

The Malaria Forum will take place on Tuesday, April 21 from 3:00 PM - 4:30 PM at 2200 Rayburn House Office Building. It is not open to the public.

(1) ASAQ is not approved in the U.S.

About sanofi-aventis

Sanofi-aventis is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients and their families. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). Sanofi-aventis U.S. is a U.S. affiliate of sanofi-aventis. For more information, visit or


    Elizabeth Baxter - sanofi-aventis, +1-908-981-5360

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Good News for Tough Times: Small, Private University Responds to Todays Economic Challenges
2. City of Warrensville Heights Residents Have Access to Easy-to-Use Prescription Drug Discount Card Launched Today
3. Issues Technical Trade Alerts on Hot Stocks in the Market Today: CAST, VM, NFLX, PFE, AA, & COF
4. National Physicians Study: Nearly One Third Would Choose Different Career Today
5. Americas Egg Farmers to Participate in Annual White House Easter Egg Roll Today
6. Video: Davis Phinney Foundation and Medtronic Raise Awareness of How to Improve Your Life Today for Those Living With Parkinsons Disease
7. MedPage Today Pledges to Maintain and Expand News Coverage in 2009
8. Mayer Labs Acquires Today(R) Sponge Distribution Rights
9. National Public Health Week Begins Today With Launch of Viral Video Campaign
10. Rxonlinetoday Launch Cyber Shop for FDA Approved Medicines
11. Smokers Have Greater Incentive to Quit, as Big Tobacco Tax Hike Goes Into Effect Today
Post Your Comments:
(Date:11/25/2015)... ... , ... Many people know of the common symptoms of low thyroid hormone ... But many people who find their cholesterol levels and weight are creeping up are ... if they don’t have any of the other symptoms. , Thyroid hormone plays a ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, DMD and ... of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses ... a dentist in Gettysburg, PA . From routine visits to cosmetic treatments, ...
(Date:11/24/2015)... Tucson, AZ (PRWEB) , ... November 24, 2015 , ... ... iPlus 2.0™ treatments from Dr. Angela Wolfman and Dr. Kedar S. Lele, who are ... used for frenectomies, cavities and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort ...
(Date:11/24/2015)... ... 2015 , ... In an article published November 12th by Obesity ... are or are not eligible for bariatric surgery. The article explains that candidates for ... than 100 pounds overweight, or have a BMI of 35 and over with at ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Developmental, commercial, and regulatory/legal strategies ... of pharmaceutical products, says GBI Research ... strategies all play a key role in boosting the ... . --> Developmental, commercial, ... boosting the profitability of pharmaceutical products, says GBI ...
(Date:11/25/2015)... 2015 ... the  "Global Drug Device Combination Products ... offering.  --> ) ... "Global Drug Device Combination Products Market ... --> Research and Markets ( ...
(Date:11/24/2015)... , Nov. 24, 2015  Natera, ... in non-invasive genetic testing and the analysis ... it will present at the 27 th ... December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., ... financial results, business activities and financial outlook. ...
Breaking Medicine Technology: